ICNMD 2020 virtual symposium: Advancing the management of Duchenne muscular dystrophy (DMD): The role of real-world evidence
Watch our virtual symposium at ICNMD 2020, which discusses long-term real-world evidence (RWE) regarding ataluren use in patients with nonsense mutation DMD (nmDMD)
Review the diagnostic and testing information used to make an accurate genetic diagnosis of DMD
RWE for determining treatment effect in patients with DMD and informing the future management of these patients is discussed
View the latest RWE for a mutation-specific DMD therapy for patients with nmDMD in clinical practice
This is a virtual symposium hosted by PTC at ICNMDigital 2020 and was organized and funded by PTC Therapeutics. This presentation was approved by the Scientific Program Committee as an independent activity held in conjunction with ICNMDigital. This presentation was not sponsored or endorsed by ICNMDigital.
This symposium recording has been chapterized to enable ease of viewing.
Register now to unlock the content
Register now to access the content on this page
Already registered?
If not, register below
MED-ALL-DMD-2200191 | December 2022
Sign in or register to access exclusive content on this site
Register here to access the content on the site MED-ALL-CORP-2200029 | December 2022
You are now leaving MEDhub, a website provided by PTC Therapeutics. This link will take you to a website to which our Privacy Statement and our Terms and Conditions do not apply.
We encourage you to read the Privacy Policy and the Terms and Conditions of every website you visit. PTC Therapeutics does not endorse and/or influence the content found on websites not owned/operated by PTC Therapeutics.
The content you are trying to access is not currently available.
We will be updating the MEDhub site regularly to provide you with up-to-date, insightful expert-led content. To be notified when new additions become available, register now.